Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Catheter Sclerotherapy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Iodine Arm | ACTIVE_COMPARATOR | Catheter-based drainage and povidone iodine sclerotherapy of non-fistulous intraabdominal abscesses. |
| Ethanol Arm | ACTIVE_COMPARATOR | Catheter-based drainage and ethanol sclerotherapy of non-fistulous intraabdominal abscesses. |
| Name | Type | Description |
|---|---|---|
| Catheter Sclerotherapy | DRUG | Place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days. |
Inclusion Criteria: * Male or female, aged over 18years * Cross-sectional imaging (CT, US, MRI) showing an intraabdominal abscess measuring at last 3cm in each dimension without fistula to the bowel or skin. * Provision of signed and dated informed consent form * Stated willingness to comply with a...
Catheter Sclerotherapy is an investigational treatment for abdominal abscess. It is being studied in a Phase 1 clinical trial to evaluate its safety and efficacy in patients with this condition. The therapy involves a catheter-based approach to deliver sclerotherapy, which is intended to treat the abscess.
Catheter Sclerotherapy is being developed by Merit Medical Systems, Inc., a company traded on the NASDAQ under the ticker MMSI. The company is conducting a Phase 1 clinical trial to assess the treatment for abdominal abscess.
Catheter Sclerotherapy is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the treatment in patients with abdominal abscess.
Catheter Sclerotherapy is being evaluated in a Phase 1 clinical trial with the identifier NCT06906029, titled "Abdominal aBscess Catheter Sclerotherapy (ABCS)." The trial is not yet recruiting and aims to enroll 60 participants in the United States.
The Phase 1 clinical trial of Catheter Sclerotherapy is randomized and active-controlled, meaning participants are assigned to receive either the investigational treatment or an active comparator. The study is not double-blinded, so both researchers and participants may know which treatment is being administered.